Crinetics Pharmaceuticals (NASDAQ:CRNX) just reported results for the first quarter of 2024.
- Crinetics Pharmaceuticals reported earnings per share of -93 cents. This was below the analyst estimate for EPS of -81 cents.
- The company reported revenue of $640,000.
- This was 146.15% better than the analyst estimate for revenue of $260,000.